Trial Profile
A Single-arm, Open-label, Phase Ⅱ Clinical Trial of Anti-PD-1 Antibody SHR-1210 or Anti-PD-L1 Antibody SHR-1316 Combined With Apatinib Mesylate as a Second-line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Feb 2024 Planned number of patients changed from 85 to 125.
- 01 Feb 2024 Planned End Date changed from 28 Feb 2023 to 30 Dec 2024.
- 20 Jan 2024 Results (n=49) assessing safety and efficacy of Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma presented at the 2024 Gastrointestinal Cancers Symposium